U.S. Markets closed
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    30,243.14
    +778.41 (+2.64%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Europe To Layout Objections to Illumina-Grail Deal: Bloomberg

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Illumina Inc (NASDAQ: ILMN) says the European Union will issue a list of objections tomorrow over the Company's $8B takeover of GRAIL, Bloomberg reports.

  • Related Link: EC Adopts Interim Measure, Tells Grail To Work On Alternatives To Illumina Deal.

  • The EU is weighing whether the deal would prevent other companies from bringing tests to market, will likely issue a so-called statement of objections.

  • Grail has no business in Europe, and a deal veto would delay the rollout of cancer tests in the region by many years, Illumina said in a briefing paper.

  • The EU's arguments that the deal may be anticompetitive are "highly speculative and unfounded by any evidence. This is not a 'killer acquisition' as Illumina and Grail are not competitors," said Illumina.

  • Illumina risks a potential $400 million fine.

  • Related: Illumina Clocks 40% Growth In Q3; Earnings Beat Expectations.

  • Price Action: ILMN shares are down 0.09% at $378.61 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.